Alpine Woods Capital Investors »

Halozyme Therapeutics shares owned by Alpine Woods Capital Investors

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Alpine Woods Capital Investors from 13F filings

Historical chart of Alpine Woods Capital Investors investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Alpine Woods Capital Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Alpine Woods Capital Investors

Quarter filed Position value Share count Share price at filing
2026-03-31 $281k 4.4k 64.63

More positions owned by Alpine Woods Capital Investors

NVIDIA Corporation (NVDA)
Broadcom (AVGO)
Wells Fargo & Company (WFC)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl C (GOOG)
L3harris Technologies (LHX)
Agnico (AEM)
Apple (AAPL)
Amgen (AMGN)
Steel Dynamics (STLD)
Cummins (CMI)
Microsoft Corporation (MSFT)
Abbvie (ABBV)
Southern Company (SO)
Pepsi (PEP)

View all positions for Alpine Woods Capital Investors

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
Vanguard Capital Management
Vanguard Portfolio Management
State Street Corporation
Invesco
Bank of America Corporation
Robeco Investment Management
Morgan Stanley
William Blair Investment Management
Geode Capital Management
Snyder Capital Management
Dimensional Fund Advisors
Arrowstreet Capital, Limited Partnership
D. E. Shaw & Co

View all funds holding Halozyme Therapeutics